plenti6-SLC7A11/xCT-V5 Citations (2)

Originally described in: The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.
Koppula P, Zhang Y, Shi J, Li W, Gan B J Biol Chem. 2017 Aug 25;292(34):14240-14249. doi: 10.1074/jbc.M117.798405. Epub 2017 Jun 19. PubMed Journal

---

Articles Citing plenti6-SLC7A11/xCT-V5

Articles
Inhibition of LSD1 induces ferroptosis through the ATF4-xCT pathway and shows enhanced anti-tumor effects with ferroptosis inducers in NSCLC. Du L, Yang H, Ren Y, Ding Y, Xu Y, Zi X, Liu H, He P. Cell Death Dis. 2023 Nov 3;14(11):716. doi: 10.1038/s41419-023-06238-5. PubMed
Pyrimidine Triones as Potential Activators of p53 Mutants. Fallatah MMJ, Demir O, Law F, Lauinger L, Baronio R, Hall L, Bournique E, Srivastava A, Metzen LT, Norman Z, Buisson R, Amaro RE, Kaiser P. Biomolecules. 2024 Aug 8;14(8):967. doi: 10.3390/biom14080967. PubMed

If you have published an article using this material, please email us at to have your article added to this page.